Sumitomo Mitsui Trust Holdings Inc. 13D and 13G filings for Syros Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-02-04 06:09 am Sale |
2021-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS |
Sumitomo Mitsui Trust Holdings Inc. | 0 0.000% |
-438,199 (Position Closed) |
Filing |
| 2021-02-05 06:10 am Sale |
2020-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS |
Sumitomo Mitsui Trust Holdings Inc. | 438,199 9.570% |
-59,267 (-11.91%) |
Filing |